Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of PTPRS elicits potent metastatic capability and resistance to temozolomide in glioblastoma.

Molecular carcinogenesis - 1 Jul 2024

Zhang Yihua, Chang Liugang, Huang Ping, Cao Min, Hong Rujun, Zhao Xinhu, He Xuzhi, Xu Lunshan

Abstract excerpt

Glioblastoma (GBM) is the most aggressive brain tumor type with worse clinical outcome due to the hallmarks of strong invasiveness, high rate of recurrence, and therapeutic resistance to temozolomide (TMZ), the first-line drug for GBM, representing a major challenge for successful GBM therapeutics. Understanding the underlying mechanisms that drive GBM progression will shed novel insight into therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Movement

Share to Drug Resistance, Neoplasm

Share to Glioblastoma

Share to Receptor-Like Protein Tyrosine Phosphatases, Class 2

Share to Temozolomide

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 38517048
DOI: 10.1002/mc.23720

Genes

PTPRS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of PTPRS elicits potent metastatic capability and resistance to temozolomide in glioblastoma.PMID 38517048Read ↗

Intracellular and extracellular domains of protein tyrosine phosphatase PTPRZ-B differentially regulate glioma cell growth and motility.Semantic proximity Read ↗

Single-cell and bulk sequencing analyses reveal the immune suppressive role of PTPN6 in glioblastomaSemantic proximity Read ↗

Targeting RGS4 Ablates Glioblastoma ProliferationSemantic proximity Read ↗

Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signalingSemantic proximity Read ↗

Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of Notch signalingSemantic proximity Read ↗

Targeting dual specificity protein kinase TTK attenuates tumorigenesis of glioblastomaSemantic proximity Read ↗

Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cellsSemantic proximity Read ↗

The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.Semantic proximity Read ↗

Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesisSemantic proximity Read ↗

Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma.Semantic proximity Read ↗

PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation.Semantic proximity Read ↗

The Role of Translocator Protein TSPO in Hallmarks of GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.